[Culture News = Reporter Sun-Hye Park] On April 28, the Korean Society of Aesthetic and Obesity Dermatology (KSAOD) held its Spring Academic Conference at E Hall, COEX. This event, the largest of its kind since the COVID-19 pandemic, saw approximately 1,800 participants filling the venue.
During the conference, REV-MED officially launched its global multicenter metaverse research platform, NovaStem.
Purpose and Innovation of NovaStem
A REV-MED representative described NovaStem as a "global multicenter metaverse research platform designed to address the challenges faced by clinics compared to university-based research infrastructures." The platform consolidates diverse clinical research efforts, improving the reliability of results while enabling global multicenter collaboration in stem cell therapy.
“This platform aims to advance collaborative global research on stem cell treatments, bringing us closer to overcoming diseases,” the representative added.
Focus on Stem Cell Therapy
The conference included sessions on stem cell therapy, following the February amendment to the Advanced Regenerative Medicine and Advanced Biopharmaceutical Safety and Support Act (ARMBSSA). Topics ranged from legislative reviews to discussions on stem cell therapies as alternatives in autoimmune disease treatment markets. The comprehensive lectures received praise from participants, including physicians, patients, and medical device companies.
Vice President Kyung-Hee Choi of the KSAOD noted, “We organized diverse lectures to explore the current and future landscape of stem cell therapy. The packed lecture halls reflect the tremendous interest in this field.”
NovaStem's Research Contributions
REV-MED utilized NovaStem to conduct research that culminated in the publication of the paper Protective Effects of BCC Against Oxidative Stress in Cardiomyocyte Cells in the Biomedical Science Letters (BSL) journal on March 31, 2024.
Source: Culture News (https://www.mhns.co.kr)
[Culture News = Reporter Sun-Hye Park] On April 28, the Korean Society of Aesthetic and Obesity Dermatology (KSAOD) held its Spring Academic Conference at E Hall, COEX. This event, the largest of its kind since the COVID-19 pandemic, saw approximately 1,800 participants filling the venue.
During the conference, REV-MED officially launched its global multicenter metaverse research platform, NovaStem.
Purpose and Innovation of NovaStem
A REV-MED representative described NovaStem as a "global multicenter metaverse research platform designed to address the challenges faced by clinics compared to university-based research infrastructures." The platform consolidates diverse clinical research efforts, improving the reliability of results while enabling global multicenter collaboration in stem cell therapy.
“This platform aims to advance collaborative global research on stem cell treatments, bringing us closer to overcoming diseases,” the representative added.
Focus on Stem Cell TherapyThe conference included sessions on stem cell therapy, following the February amendment to the Advanced Regenerative Medicine and Advanced Biopharmaceutical Safety and Support Act (ARMBSSA). Topics ranged from legislative reviews to discussions on stem cell therapies as alternatives in autoimmune disease treatment markets. The comprehensive lectures received praise from participants, including physicians, patients, and medical device companies.
Vice President Kyung-Hee Choi of the KSAOD noted, “We organized diverse lectures to explore the current and future landscape of stem cell therapy. The packed lecture halls reflect the tremendous interest in this field.”
NovaStem's Research Contributions
REV-MED utilized NovaStem to conduct research that culminated in the publication of the paper Protective Effects of BCC Against Oxidative Stress in Cardiomyocyte Cells in the Biomedical Science Letters (BSL) journal on March 31, 2024.
Source: Culture News (https://www.mhns.co.kr)